PropThink: Positive Naloxegol Results; NKTR Powering Through Analyst Downgrade

PropThink: Positive Naloxegol Results; NKTR Powering Through Analyst Downgrade

By David Moskowitz

Nektar Therapeutics (NKTR) hosted a conference call Monday morning, highlighting the successful results from two Phase III trials and one safety extension study for Naloxegol, the company`s treatment for opioid induced constipation (OIC) in patients taking chronic pain killers for non-cancer related pain. Naloxegol is partnered with AstraZeneca (AZN) and is a key driver of the NKTR story, estimated to represent about 25%-30% of Wall Street analysts` long-term price targets. The three trials that reported out include: KODIAC-04, KODIAC -05, and KODIAC -07. KODIAC-04 and -05 are pivotal Phase III 12-week efficacy and safety trials, while KODIAC-07 is the 12-week safety extension of KODIAC-04. Both KODIAC-04 and KODIAC-05 evaluated two doses of Naloxegol (12.5mg and 25mg) administered once-daily. The primary endpoint in both trials was the percentage of OIC responders vs. placebo over 12 weeks of treatment. In the trials, a responder was defined as having at least three spontaneous bowel movements (SBMs) per week, with at least one SBM per week increase over baseline for at least nine out of 12 weeks, and at least three of the last four weeks. For statistical significance to be achieved in each trial, at lease one of the two Naloxegol doses needed to achieve a p-value <0.025 vs. placebo. These are high hurdles for success, and importantly, in the KODIAC-04 trial, both Naloxegol doses demonstrated statistically significant results for the primary endpoint (P-values of 0.015 and 0.001 for the 12.5mg and 25mg doses, respectively). In KODIAC-05, Naloxegol 25mg achieved statistical significance for the primary endpoint (P-value of 0.021). According to the company, the 25mg dose remains the target dose, and is key in the long-term safety extension studies. Safety data for both trials indicate that Naloxegol is generally well-tolerated with common adverse events (AEs) including bowel pain and nausea, which are expected side effects in this treatment area. Importantly, the company noted on its conference call that it saw no cardiovascular (CV) risk signals associated with Naloxegol in the trials. CV events in the trials were low overall, and an analysis by a third party concluded that Naloxegol treatment was not a cause for these events.

While these safety and efficacy results support potential approval of the drug, some analysts remain skeptical on treatments for OIC, noting that the FDA has increased its focus on CV safety for potential OIC therapies. Monday morning, brokerage firm Jeffries downgraded shares of NKTR (from Outperform to Neutral), citing new disclosures from competitors Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX), which together are developing their drug, Relistor for OIC. The new disclosure cites that Relistor may be required to undergo a very large well-controlled study on CV safety prior to approval, based on information in the complete response letter (CRL) issued by FDA for Relistor. Notably, NKTR added a new risk disclosure in its recent 10Q regarding regulatory uncertainty due to the potential for CV risk, raising a potential red flag for Naloxegol. Analysts supporting NKTR note that the Phase III program for Naloxegol is the most comprehensive in the category, with >2,000 patients being evaluated in pivotal trials and long-term safety studies.

Driven by major pharmaceutical company AstraZeneca, the Phase III program was designed from the start to evaluate treatment with Naloxegol in a chronic use setting. Data announced from the KODIAC-07 safety extension study should calm investors today, as NKTR notes that the occurrence of adverse events (AEs) and serious adverse events (SAEs) was lower than in KODIAC-04 and -05, indicating that the treatment may actually become better tolerated over time. Again, the company`s comments on its conference call that a third party concluded that there was no CV risk associated with the treatment, should also give investors confidence in the potential approval of Naloxegol. Notably, enrolment is complete for the KODIAC-08 trial, an open-label, 1,200 patient, randomized, 52-week long-term safety study, and the company and its partner could announce results in 2Q 2013. It appears that AZN was clearly anticipating FDA scrutiny on long-term safety, and the KODIAC-08 trial should satisfy FDA`s desire to see a large, long-term, safety database for the drug. Continue reading this article at Propthink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.

Disclaimer:

You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.